Weight-loss injections, widely known for their role in helping people shed pounds, could also have the potential to extend the lives of some patients with advanced cancer that has metastasized to the brain, according to new research. These medications belong to a class called GLP-1 receptor agonists, which include drugs like Wegovy and Ozempic. Originally created to manage type 2 diabetes, they’ve garnered global attention in recent years due to their notable weight-loss effects.
This recent study doesn’t claim these injections directly treat cancer, but suggests a more subtle benefit: they might help some seriously ill patients live longer. The research specifically investigates the impact on brain metastases, which occur when cancer cells travel from organs like the lungs, breasts, or skin to form tumors in the brain. This condition often indicates a late, more dangerous stage of cancer.
Many individuals with brain metastases also have type 2 diabetes, complicating their condition. High blood sugar levels can trigger ongoing inflammation, damage blood vessels, and weaken the body’s ability to recover. In clinical practice, steroids are frequently prescribed to reduce brain swelling and manage symptoms, but they tend to raise blood sugar, complicating diabetes control.
This has prompted researchers to consider whether GLP-1 receptor drugs could provide additional benefits beyond blood sugar regulation. Laboratory studies indicate these drugs may protect brain cells, lessen inflammation, and support healthy blood flow within the brain. However, real-world clinical data on how patients with both diabetes and brain metastases fare when taking these medications has been limited—until now.
The new study, published in JAMA Network Open, utilized a large database of anonymized health records from 151 hospitals worldwide, focusing on adults with cancer, type 2 diabetes, and brain metastases, between 2018 and 2024. Researchers examined whether these patients had been prescribed GLP-1 drugs—such as semaglutide, dulaglutide, liraglutide, or tirzepatide—around the time their diagnoses were made.
To ensure fair comparisons, patients treated with GLP-1 medications were matched with similar individuals who had not received them, considering factors like age, gender, type of cancer, other health conditions, and treatments including chemotherapy, radiation, and steroids. While no method is perfect, matching helps minimize bias and makes the results more reliable.
Out of more than 19,000 patients analyzed, 866 had been treated with a GLP-1 drug, while over 11,000 had not. After pairing similar patients, the study focused on two groups of 850 individuals each, tracking survival over three years following the diagnosis of brain metastases.
Results showed that those taking GLP-1 medications were significantly less likely to die during that period—about 37% less likely compared to those not on these drugs. This survival benefit was consistent across various cancer types, including lung, breast, and melanoma, and was observed across different drugs within the GLP-1 class.
Further comparison with other recent diabetes treatments, like SGLT2 inhibitors and DPP-4 inhibitors, revealed that GLP-1 drugs still offered a survival advantage. This suggests that the benefit isn’t solely due to better blood sugar control but may involve specific actions of GLP-1 signaling.
However, the researchers emphasized a key limitation: the study was retrospective, based on existing medical records rather than controlled clinical trials. To definitively establish cause and effect, randomized studies are necessary, where patients are assigned treatments in a controlled manner and followed prospectively.
How might these medications help patients with brain metastases? One possibility is that they indirectly improve overall health by better managing diabetes—leading to weight loss, improved cardiovascular health, and enhanced ability to tolerate treatments. There could also be direct effects in the brain: GLP-1 receptors exist in brain tissue and are involved in controlling inflammation, protecting nerve cells, and maintaining the blood-brain barrier—a protective layer that blocks harmful substances from entering the brain.
Animal studies support this idea, showing activation of GLP-1 receptors can reduce brain cell damage and support their proper functioning. This might make the brain more resilient against metastatic tumors or create an environment less conducive to cancer growth. The clinical findings align with these hypotheses, though the precise mechanisms remain to be fully understood.
It’s important for patients and their families to recognize what this research means—and what it doesn’t. The study does not suggest that individuals with brain metastases should start GLP-1 drugs immediately, nor that these medications replace standard cancer treatments such as radiation, surgery, targeted therapies, or immunotherapy. The observed benefits were specific to people who already had type 2 diabetes, and these drugs can cause side effects like nausea and vomiting, with rare but serious risks.
Those considering these medications should consult with their healthcare providers for personalized advice, rather than making decisions based solely on this recent research. Still, these findings open an exciting avenue for future studies exploring the link between metabolism, brain health, and cancer survival. If ongoing research confirms that GLP-1 drugs truly boost survival rates in patients with brain metastases and diabetes, they could eventually become part of supportive care approaches for this challenging complication.
